Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.63 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid Methyl Ester SCHEMBL27529952 | 0.91 | MEN1 (0.58) | MEN1KMT2APABPC1P4HTMMAOB | |
| Formic Acid SCHEMBL27523068 | 0.91 | MEN1 (0.62) | MEN1KMT2APABPC1P4HTMMAOB | |
| SCHEMBL5183487 | 0.88 | APP (0.56) | MEN1KMT2APABPC1MAOBRAB9A | |
| SCHEMBL6208078 | 0.86 | MEN1 (0.60) | MEN1KMT2APABPC1MAOBLMNA | |
| SCHEMBL17544483 | 0.83 | NPC1 (0.51) | MEN1KMT2APABPC1RAB9A | |
| SCHEMBL5183041 | 0.83 | MEN1 (0.56) | MEN1KMT2APABPC1MAOBLMNA | |
| SCHEMBL6209712 | 0.82 | MEN1 (0.56) | MEN1KMT2APABPC1MAOBLMNA | |
| SCHEMBL1936414 | 0.82 | P4HTM (0.48) | MEN1KMT2APABPC1P4HTMMAOB | |
| SCHEMBL6645927 | 0.80 | P4HTM (0.60) | MEN1KMT2APABPC1P4HTMMAOB | |
| SCHEMBL6684242 | 0.79 | SYK (0.52) | CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770240-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| CN-107074807-A | Compositions and methods for inhibiting histone demethylase | 吉利德科学公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3186238-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| CN-102448937-A | Aryl Substituted Carboxamide Derivatives As Calcium Or Sodium Channel Blockers | RAQUALIA PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| CN-102256983-A | Spirooxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-11-23 | — | — | CN | disclosed |
| CN-101384258-A | FGF receptor agonist dimeric compounds | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
| CN-1237051-C | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGRO SCIENCES LLC (US) | 2006-01-18 | — | — | CN | disclosed |
| CN-1208321-C | Fungicidal heterocyclic aromatic amides and their compositions methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2005-06-29 | — | — | CN | disclosed |
| CN-1450993-A | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1390204-A | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGRO SCIENCES LLC (US) | 2003-01-08 | — | — | CN | disclosed |
| CN-1329596-A | Pyridinecarboxamide derivative and pest control agent containing same as active ingredient | MEIJI SEIKA KAISHA (JP) | 2002-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | MEN1 3634/4885KMT2A 34/4885PABPC1 1892/4885 |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | MEN1 2871/4885KMT2A 1492/4885PABPC1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.